Benutzer: Gast  Login
Mehr Felder
Einfache Suche
Titel:

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.

Dokumenttyp:
Clinical Trial; Journal Article; Multicenter Study
Autor(en):
Herrlinger, K R; Diculescu, M; Fellermann, K; Hartmann, H; Howaldt, S; Nikolov, R; Petrov, A; Reindl, W; Otte, J M; Stoynov, S; Strauch, U; Sturm, A; Voiosu, R; Ammendola, A; Dietrich, B; Hentsch, B; Stange, E F
Abstract:
Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma. The objective of the study was to explore the efficacy, safety and tolerability of vidofludimus in steroid-dependent inflammatory bowel disease (IBD).The open label uncontrolled ENTRANCE study (ClinicalTrials.gov NCT00820365) has been conducted at 13 study centers in Germany, Bulgari...     »
Zeitschriftentitel:
J Crohns Colitis
Jahr:
2013
Band / Volume:
7
Heft / Issue:
8
Seitenangaben Beitrag:
636-43
Sprache:
eng
Volltext / DOI:
doi:10.1016/j.crohns.2012.09.016
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/23078909
Print-ISSN:
1873-9946
TUM Einrichtung:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX